This year AACR is showcasing quite a few early approaches emerging from company pipelines on the KRAS front, including numerous upstream (pan SOS:RAS) and downstream or even cross-stream agents, which may potentially be combined down the road to improve patient outcomes beyond what we see now with selective KRAS inhibitors.

In this review we highlight five key development areas, which have emerged from the meeting so far and give us glimpses into where the puck is heading next…

BSB subscribers can read our latest conference coverage from AACR plus commentary and analysis – you can either log-in or click to access.

This content is restricted to subscribers

Posted by